AbCellera Biologics Inc (NASDAQ: ABCL) on Monday, plunged -3.69% from the previous trading day, before settling in for the closing price of $4.34. Within the past 52 weeks, ABCL’s price has moved between $3.87 and $8.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 387.52%. The company achieved an average annual earnings per share of 4.48%. With a float of $205.17 million, this company’s outstanding shares have now reached $290.82 million.
Let’s determine the extent of company efficiency that accounts for 586 employees.
AbCellera Biologics Inc (ABCL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of AbCellera Biologics Inc is 29.92%, while institutional ownership is 38.39%. The most recent insider transaction that took place on May 26 ’23, was worth 997,728. In this transaction 10% Owner of this company bought 153,000 shares at a rate of $6.52, taking the stock ownership to the 56,012,493 shares. Before that another transaction happened on May 26 ’23, when Company’s Chief Financial Officer bought 14,500 for $6.85, making the entire transaction worth $99,325. This insider now owns 153,000 shares in total.
AbCellera Biologics Inc (ABCL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.48% per share during the next fiscal year.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
AbCellera Biologics Inc (ABCL) is currently performing well based on its current performance indicators. A quick ratio of 7.32 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Looking closely at AbCellera Biologics Inc (NASDAQ: ABCL), its last 5-days average volume was 1.15 million, which is a drop from its year-to-date volume of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 16.54%. Additionally, its Average True Range was 0.22.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 1.57%, which indicates a significant decrease from 5.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.40% in the past 14 days, which was higher than the 54.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.80, while its 200-day Moving Average is $5.24. However, in the short run, AbCellera Biologics Inc’s stock first resistance to watch stands at $4.30. Second resistance stands at $4.41. The third major resistance level sits at $4.49. If the price goes on to break the first support level at $4.11, it is likely to go to the next support level at $4.03. Should the price break the second support level, the third support level stands at $3.92.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
Market capitalization of the company is 1.22 billion based on 292,782K outstanding shares. Right now, sales total 38,030 K and income totals -146,400 K. The company made 9,180 K in profit during its latest quarter, and -47,150 K in sales during its previous quarter.
